-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) PT Raised to $39 at BTIG
-
-
-
-
-
-
-
Denali shares jump on FDA approval of Hunter syndrome drug
-
-
-
-
-
-
-
Goldman Sachs: 'we view DNLI as attractive given the aforementioned dynamics'
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 1c
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c
-
428,017 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

